Document is current
Any future updates will be listed below
-
Authors
Kaisey, Marwa http://orcid.org/0000-0001-6019-7317
Lashgari, Ghazal
Fert-Bober, Justyna
Ontaneda, Daniel
Solomon, Andrew J.
Sicotte, Nancy L.
-
Funding
Funding for this research was provided by:
National Multiple Sclerosis Society (RFA-2104-37511)
Race to Erase MS
Cedars-Sinai Precision Health Group
- License Information
-
More Information
Article History
Accepted: 12 August 2022
First Online: 21 October 2022
Declarations
:
: Marwa Kaisey MD: Consulting or Advisory boards for Alexion, Biogen, Genentech, and Novartis.Ghazal Lashgari MD: The author does not have existing conflict of interest. Justyna Fert-Bober PhD: The author does not have existing conflict of interest.Daniel Ontaneda MD, PhD: Research support from the National Institutes of Health, Department of Defense, National Multiple Sclerosis Society, Patient Centered Outcomes Research Institute, Race to Erase MS Foundation, Genentech, Genzyme, and Novartis. Consulting fees from Biogen Idec, Genentech/Roche, Genzyme, Janssen, Novartis, and Merck.Andrew J. Solomon MD: Consulting or Advisory Boards: EMD Serono, Biogen, Alexion, Celgene, Genentech, Greenwich Biosciences, TG Therapeutics, Octave Bioscience; Non- promotional speaking: EMD Serono; Research Funding: Biogen, Bristol Myers Squibb; Contracted Research: Biogen, Novartis, Actelion, Genentech/Roche, Sanofi.Nancy L. Sicotte MD: The author does not have existing conflict of interest.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
